文献速递产科麻醉

去甲肾上腺素体重调整输注预防腰硬联合麻醉剖宫产低血压的随机双盲剂量反应研究

A randomised double-blind dose-response study of weight-adjusted infusions of norepinephrine for preventing hypotension during combined spinal-epidural anaesthesia for Caesarean delivery.
PubMed 文献 · Br J Anaesth · 2020-01-17

该双盲随机对照试验纳入80例择期剖宫产产妇,在腰硬联合麻醉后立即以0.025、0.05、0.075或0.10 μg kg-1 min-1速率预防性输注去甲肾上腺素。主要终点为分娩前低血压(收缩压较基线下降≥20%或≤90 mm Hg)未发生。低血压发生率随剂量增加而降低(P<0.0001),ED50和ED90分别为0.029和0.080 μg kg-1 min-1。

要点

  • 去甲肾上腺素预防剖宫产腰硬联合麻醉低血压的ED90为0.080 μg kg-1 min-1。
  • 低血压发生率在0.025至0.10 μg kg-1 min-1剂量间随剂量增加而降低。
  • 反应性高血压发生率随去甲肾上腺素剂量增加而升高(P=0.002)。

核心结论

  • 在本研究条件下,去甲肾上腺素0.08 μg kg-1 min-1输注可有效预防90%患者的低血压。

研究设计与样本

  • 双盲随机对照试验,80例择期剖宫产产妇随机分为四组,每组20例,分别接受0.025、0.05、0.075、0.10 μg kg-1 min-1去甲肾上腺素预防性输注,于腰硬联合麻醉诱导后立即开始。

主要发现

  • 低血压发生率在N1至N4组分别为11/20(55%)、6/20(30%)、2/20(10%)、1/20(5%),P<0.0001。
  • 去甲肾上腺素预防低血压的ED50为0.029 μg kg-1 min-1(95%CI -0.002至0.043),ED90为0.080 μg kg-1 min-1(95%CI 0.065至0.116)。
  • 反应性高血压发生率随去甲肾上腺素剂量增加而升高(P=0.002),其他不良反应组间相似。

关键数值与推荐

  • 低血压定义为分娩前收缩压较基线下降≥20%或≤90 mm Hg。
  • ED50和ED90通过概率单位回归计算。

临床怎么用

  • 去甲肾上腺素0.08 μg kg-1 min-1可作为预防剖宫产腰硬联合麻醉低血压的起始输注速率参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Norepinephrine infusion has been suggested as an effective method for preventing hypotension during spinal anaesthesia for Caesarean delivery. However, optimal dosing regimens for norepinephrine have not been well established. This study aimed to determine the dose-response characteristics of a weight-adjusted fixed-rate infusion of norepinephrine to prevent hypotension during neuraxial anaesthesia for Caesarean delivery. METHODS: In a double-blind, randomised controlled trial, 80 parturients having elective Caesarean delivery received a prophylactic norepinephrine infusion at 0.025 μg kg-1 min-1 (Group N1), 0.05 μg kg-1 min-1 (Group N2), 0.075 μg kg-1 min-1 (Group N3), or 0.10 μg kg-1 min-1 (Group N4), starting immediately after induction of combined spinal-epidural anaesthesia. The primary outcome was non-occurrence of hypotension, defined as a decrease in systolic arterial pressure ≥20% below baseline value or to ≤90 mm Hg, before delivery. Values for 50% effective dose (ED50) and ED90 were calculated using probit regression. RESULTS: The incidence of hypotension was 11/20 (55%), 6/20 (30%), 2/20 (10%), and 1/20 (5%) in Groups N1, N2, N3, and N4, respectively (P<0.0001). The ED50 and ED90 (95% confidence interval) of norepinephrine infusions for preventing hypotension were 0.029 (-0.002 to 0.043) and 0.080 (0.065-0.116) μg kg-1 min-1, respectively. The incidence of reactive hypertension increased with increasing norepinephrine dose (P=0.002). Other adverse effects were similar among groups. CONCLUSIONS: Under the conditions of this study, an infusion of norepinephrine 0.08 μg kg-1 min-1 was effective for preventing hypotension in 90% of patients. This information should provide a guide for initiating norepinephrine infusions. CLINICAL TRIAL REGISTRATION: ChiCTR1900022322 at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/enindex.aspx).

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Fu F, Xiao F, Chen W, et al. A randomised double-blind dose-response study of weight-adjusted infusions of norepinephrine for preventing hypotension during combined spinal-epidural anaesthesia for Caesarean delivery. Br J Anaesth. 2020. PMID: 31959386. doi:10.1016/j.bja.2019.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。